An American Society of Cataract and Refractive Surgery task force made an official statement on monitoring and future intervention for patients with the CyPass implant after Alcon voluntarily withdrew the device from the market in late August due to safety concerns.
The 5-year results of the COMPASS-XT study showed patients implanted with the CyPass device who underwent cataract surgery experienced more endothelial cell loss compared with patients who underwent cataract surgery alone. Baseline cell counts were 2,432 cells/mm2 in CyPass patients and 2,433 cells/mm2 in control subjects. At 5
Uncategorized